1

Medical data is for informational purposes only. You should always consult your family physician, or one of our referral physicians prior to treatment.

The Journal

Of The

Academy of

Rheumatoid Diseases

Volume 1

Number 2

Officers and Board Members:

President (Chairman): Gus J. Prosch, Jr., M.D.

Vice-Chairman: Sheldon Nelson, D.O.

Executive Director/Secretary: Wayne Martin, B.S.

Medical Journal Editor: Robert Bingham, M.D. (1986); Stephan

Cooter, Ph.D. (1994)

Chief Editor/Treasurer: Robert Bingham, M.D. (1986)

Board Members:

Robert Bingham, M.D.; Warren M. Levin, M.D.; W. W. Mittelstadt,

D.O., M.D.; Archimedes A. Concon, M.D.; Harley Robinson, D.O;

Albert Jellen, M.D.

Research Advisory Board:

Harold Buttram, M.D.; Lazlo I. Belenyessy, M.D.; Dr. Paul K.

Pybus

In Memoriam to Robert Bingham, the 1994 republication of The

Journal of the Rheumatoid Disease Medical Association

?

, is being

made by The Arthritis Trust of America. Editorial and subscription

office: c/o Perry A. Chapdelaine, Sr., The Arthritis Trust of America

®

,

7376 Walker Road, Fairview, TN. 1986 by The Rheumatoid Dis-

ease Medical Association, ISBN 0-930991-10-9.

Table of Contents

Volume 1

Number 2

Editorial

Secretary’s Report

The Free-Living Amoebic Causation and Cure of Activity in

Rheumatoid Diseases Roger Wyburn-Mason

Arteriosclerosis — A Vital Message to My Patients

Gus J. Prosch, Jr., M.D. and Wyatt C. Simpson, M.D.

Anti-Amoebic Treatment of the Rheumatoid Diseases (Part 2)

Gus J. Prosch, Jr., M.D.

Boron in Medicine — An Up-Date Rex E. Newnham, B.Sc., D.O.

The Rheumatoid Disease Foundation (now The Arthritis Trust

of America)

The Academy of Rheumatoid Diseases

The Rheumatoid Disease Foundation

[The Arthritis Trust of America]

The Rheumatoid Disease Foundation was chartered as a non-

profit, charitable organization in the State of Tennessee, October

13, 1982, and received its retroactive tax-exempt status from IRS

March 29, 1983.

The purpose of The Rheumatoid Disease Foundation is:

1. To disseminate the scientific findings of Professor Roger

Wyburn-Mason, that the Limax amoeba is the source-cause of

most forms of Rheumatoid Diseases; [although it appears now that

this theory was incorrect, the treatments developed from it have

been successful]

2. To contract with professional scientific and medical organi-

zations for research and develop mental studies related to the cure

and/or remission of Rheumatoid Diseases;

3. To fund basic research with such professional organiza-

tions;

4. To provide free and/or contributory treatment to needy

victims of Rheumatoid Diseases;

5. To solicit funds from the general public in support of the

above programs.

Editorial

Too many patients have accepted verbatim the propaganda

and money-raising line of the Arthritis Foundation — “There is no

known cause for arthritis and no known cure.” This may be a good

emotional approach to the public in soliciting funds, but it gives an

arthritis patient no hope in seeking a recovery from the disease. It

may steer the person suffering from arthritis to the rheumatologist

and to content him into accepting palliative treatment. But it is

fatalistic to any hope of a permanent remission or “cure.”

Those of us who have been offering our patients a “total arthri-

tis program of treatment” with emphasis on improving their health

and resistance to disease — in addition to the usual drug treatments

when necessary — by improving the patient’s diet, giving food and

vitamin supplements, prescribing exercises and physical therapy,

have seen many more recoveries from arthritis than the averages

reported in the medical literature.

And those physicians who are bold enough and experienced

enough to use alternative treatments and “approved drugs for un-

proven indications” have even higher percentages of improvement

and remissions in their arthritis patients.

Examples of these are the use of therapeutic doses of minerals

and vitamins, herbal extracts such as Yucca, non-specific vaccine

immunizations to build up patient resistance to infections, high

protein and complex carbohydrate diets, and the prescribing of

anti-protozoal drugs rather than the anti-malarials.

A journal such as this will bring to the practicing physician the

clinical results of many physicians in many countries who are on

the forefront of Arthritis Treatment. They may be using “orphan

drugs” whose patents have expired so that no pharmaceutical com-

pany has any interest in financing their clinical testing for “effi-

cacy.” They may have discovered some new use of an old remedy

or treatment. They may have by serendipity observed a patient

improve or recover with some new or different substance or method.

All of these can be reported in this publication. The test of a

new method or treatment should be: “It must be beneficial to the

patient, and it must do no harm.” In other words, it is the Risk/

Benefit Ratio that is important — not just that it has been “Ap-

proved” for advertising by the manufacturer or distributor by the

Food and Drug Administration.

Why the medical profession has allowed the government and

the legal professions to control our “standards of practice” is some-

thing I will never understand. Only physicians know what is best

for their patients, and their judgments should not be controlled by

laymen — only their peers.

The Academy of Rheumatoid Diseases solicits members who

are open-minded and progressive in their arthritis treatment and in

their own clinical experiences and investigations. We will welcome

papers and case reports which will help and encourage other doc-

tors in the management of this large family of diseases, “about

which more is unknown than known.” This Journal may play an

®